New Jersey dangles tax savings in front of Teva in bid to bag US HQ as revamp costs 200-plus jobs
In turmoil lies opportunity. And that may play out well for the New Jersey biopharma industry.
The state economic development group has laid out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
